56°F
weather icon Light Rain

Health advisers back J&J’s COVID booster shot

WASHINGTON — U.S. health advisers endorsed a booster of Johnson &Johnson’s COVID-19 vaccine Friday, citing concern that Americans who got the single-dose shot aren’t as protected as those given two-dose brands.

J&J told the Food and Drug Administration that an extra dose adds important protection as early as two months after initial vaccination — but that it might work better if people wait until six months later. Unable to settle the best timing, the FDA’s advisory panel voted unanimously that the booster should be offered at least two months after people got their earlier shot.

“I think this frankly was always a two-dose vaccine,” said FDA adviser Dr. Paul Offit of Children’s Hospital of Philadelphia. “It would be hard to recommend this as a single-dose vaccine at this point.”

The FDA isn’t bound by the recommendation as it makes a final decision. And adding to the debate’s complexity, new research also suggests that J&J recipients might have a stronger immune response if their booster dose is from a competing brand.

Preliminary results from an ongoing study of different ways to “mix and match” different shots showed that a booster of any sort revved up people’s levels of virus-fighting antibodies — at least for a few weeks. And the most dramatic jump came from giving a Pfizer or Moderna shot after the single-dose J&J vaccination.

FDA’s advisers didn’t vote on whether that should be recommended but told the government to allow flexibility with boosters, saying there were no safety red flags even if it’s not yet clear just how much difference, if any, mixing and matching may make in long-term protection.

“In the real world all these kind of combinations are already happening, so I think it’s a matter of some urgency for the FDA to help sort out what is admittedly a complicated and challenging scenario,” said Dr. Ofer Levy of Boston Children’s Hospital.

The government says that all three U.S. vaccines continue to offer strong protection against hospitalization and death from COVID-19 and that the priority is getting first shots to the 66 million eligible but unvaccinated Americans who are most at risk. But with the spread of the extra-contagious delta variant and signs of waning immunity against milder infections, the nation is moving toward a broader booster campaign.

Last month Pfizer boosters started being offered to seniors and younger adults at high risk from COVID-19 because of poor health, jobs or living conditions — at least six months after their initial vaccination. Thursday, the FDA advisory panel recommended the same approach for half-dose Moderna boosters.

But J&J’s vaccine has consistently shown lower effectiveness levels across a series of studies — and the FDA panel settled on another shot for any recipient 18 or older at least two months after their first vaccination.

“This is really — with the second dose — bringing it, I think, on par with those other vaccines in terms of effectiveness,” said Dr. Archana Chatterjee of Rosalind Franklin University.

The FDA will use its advisers’ recommendations to decide whether to authorize boosters for both J&J and Moderna. Next, the Centers for Disease Control and Prevention would rule on who should roll up their sleeves.

The majority of the 188 million Americans who are fully vaccinated against COVID-19 have received the Pfizer or Moderna options. J&J recipients account for only about 15 million.

The J&J vaccine was highly anticipated for its one-and-done formulation. But its rollout was hurt by a series of troubles including manufacturing problems and some rare but serious side effects including a blood clot disorder and a neurological reaction called Guillain-Barre syndrome.

Don't miss the big stories. Like us on Facebook.
THE LATEST
1st case of omicron variant in US identified in returning traveler

The U.S. recorded its first confirmed case of the omicron variant Wednesday as scientists around the world raced to establish whether the new, mutant version of the coronavirus is more dangerous than previous ones

Nevada surpasses 8K COVID-19 deaths

Updated state data showed 840 new COVID-19 cases and 32 deaths over the previous day, bringing totals to 457,643 cases and 8,017 deaths.